Abstract:The human leucine-rich repeats and immunoglobulin-like domains (LRIG) gene family contains LRIG1, 2 and 3, encoding integral membrane proteins with an ectodomain, a transmembrane domain and a cytoplasmic tail. LRIG1 negatively regulates multiple receptor tyrosine kinases signaling including the epidermal growth factor receptor (EGFR) and is a proposed tumor suppressor. The soluble LRIG1 ectodomain is demonstrated to be shed naturally and inhibit the progression of glioma. However, little is known regarding the functions of LRIG2. In oligodendroglioma, LRIG2 expression is associated with poor survival, suggesting that LRIG2 might have different functions compared with LRIG1. Since soluble LRIG1 ectodomain has a similar function to the full-length LRIG1, we hypothesize that the different roles exerted by LRIG2 and LRIG1 result from the difference of their ectodomains. Here, we addressed the functions of LRIG2 and LRIG2 ectodomain in the proliferation and apoptosis of glioma and the possible underlying mechanisms. Firstly, we found that LRIG2 expression levels positively correlated with the grade of glioma. Further, we demonstrated for the first time that soluble LRIG2 ectodomain was capable of being released from glioblastoma cells and exerted a pro-proliferative effect. Overexpression of LRIG2 ectodomain promoted the proliferation and inhibited the apoptosis of glioblastoma cells in vitro and in vivo in a similar manner to the full-length LRIG2. Both full-length LRIG2 and LRIG2 ectodomain were found to physically interact with EGFR, enhance the activation of EGFR and its downstream PI3 K/Akt pathway. To our knowledge, this is the first report demonstrating that soluble LRIG2 ectodomain is capable of being released from glioblastoma cells and exerts a similar role to the full-length LRIG2 in the regulation of EGFR signaling in the progression of glioblastoma. LRIG2 ectodomain, with potent pro-tumor effects, holds promise for providing a new therapeutic target for the treatment of glioblastoma.

LRIG1, human EGFR inhibitor, reverses multidrug resistance through modulation of ABCB1 and ABCG2.

LRIG1 Dictates the Chemo-Sensitivity of Temozolomide (TMZ) in U251 Glioblastoma Cells Via Down-Regulation of EGFR/topoisomerase-2/Bcl-2

LRIG1 Enhances Chemosensitivity by Modulating BCL-2 Expression and Receptor Tyrosine Kinase Signaling in Glioma Cells.

miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.

LRIG 1 Enhances the Radiosensitivity of Radioresistant Human Glioblastoma U 251 Cells Via Attenuation of the EGFR / Akt Signaling Pathway

LRIG1 Improves Chemosensitivity Through Inhibition of BCL-2 and MnSOD in Glioblastoma

A Role for LRIG1 in the Regulation of Malignant Glioma Aggressiveness.

Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling

Restoration of LRIG1 suppresses bladder cancer cell growth by directly targeting EGFR activity

Increased Leucine-Rich Repeats and Immunoglobulin-Like Domains 1 Expression Enhances Chemosensitivity in Glioma

Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR

[LRIG3 Gene Regulates Biological Activity of GL15 Cell Line].

CIGB-300 reverses chemo-resistance in MDR1-transfected lung squamous cancer cells

LRIG1 regulates invasion and migration of human gliomas through SNAI2 and E-cadherin

LRIG1 Combined with Cisplatin Enhances Bladder Cancer Lesions Via a Novel Pathway.

LRIG1, a 3p tumor suppressor, represses EGFR signaling and is a novel epigenetic silenced gene in colorectal cancer.

Effects of LRIG1 Expression on Radiosensitivity of Human Glioma Cells and the Possible Mechanism

Relationship Between Leucine-Rich Repeats and Immunoglobulin-Like Domains 1 with Chemotherapy Sensitivity in Glioma Cells

LRIG 1-modulated invasion and metastasis of human gliomas through regulation of SNAI 2 and E-cadherin

Effect of over-expressed LRIG3 on cell cycle and survival of glioma cells

Soluble Lrig2 Ectodomain Is Released From Glioblastoma Cells And Promotes The Proliferation And Inhibits The Apoptosis Of Glioblastoma Cells In Vitro And In Vivo In A Similar Manner To The Full-Length Lrig2